Stock Report

All about this stock under one free report Last Updated: 08-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Ligand Pharmaceuticals (LGND) Key Ratios

Stock Card factsheet share-fund-plan-icon

$285.60

up-down-arrow $1.33 (0.47%)

As on 04-Sep-2026 16:00EDT

Market cap

info icon

$5,694 Mln

Revenue (TTM)

info icon

$291 Mln

P/E Ratio

info icon

29.8

P/B Ratio

info icon

5.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 23.14 33.73 54.89 22.87 2.91
EBIT 385.64 419.59 396.48 23.23 54.03
Net Profit 463.49 900.78 359.97 93.65 32.72
EPS 430.97 813.20 337.28 86.95 27.93
Book Value -- -- 9.95 10.80 2.50
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 37.2033.7882.5059.293.32
Net Margin info --24.8967.88----
Return on equity info 6.994.7519.8713.47-0.53
Return on Capital info 5.923.81--10.79-0.52
Return on Assets info 5.403.4512.159.95-0.47
Debt to Equity (x) info ----1.160.440.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
10.79
-0.52
7.49
-3.64
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

19.87

Higher than Peers by 0.90

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
19.87
13.47
-0.53
8.03
-4.70
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

12.15

Higher than Peers by 9.29

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
12.15
9.95
-0.47
6.73
-3.24
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

82.50

Higher than Peers by 66.68

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
82.50
59.29
3.32
48.98
19.27
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

67.88

Higher than Peers by 59.65

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
67.88
46.42
-2.41
39.72
-17.00
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

54.89

Higher than Peers by 46.83

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
54.89
0.60
0.27
-0.33
-0.19
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

396.48

Higher than Peers by 388.21

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
396.48
2,761.57
-91.36
70.10
-58.82
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

359.97

Higher than Peers by 352.23

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
359.97
3,186.63
-107.73
256.33
-158.39
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

337.28

Higher than Peers by 326.88

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
337.28
28.71
-1.07
2.49
-1.58
Peer Median
10.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

6.56

Higher than Peers by 1.68

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
6.56
--
--
--
--
Peer Median
4.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

1.16

Higher than Peers by 0.56

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
1.16
0.44
0.01
0.01
0.15
Peer Median
0.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.00
0.00
0.00
0.00
0.13
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

31.18

Higher than Peers by 29.53

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
31.18
22.23
8.93
14.15
2.67
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

30.96

Higher than Peers by 29.76

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
30.96
21.98
8.55
12.72
2.53
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

39.44

Higher than Peers by 34.67

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
39.44
33.71
1.83
98.04
21.02
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

24.07

Higher than Peers by 2.79

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
24.07
22.77
25.40
29.94
17.85
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.18

Lower than Peers by 0.22

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.18
0.21
0.19
0.17
0.19
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
70.50
89.34
103.40
117.89
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
644.28
628.04
194.16
140.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
234.84
126.32
40.30
47.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
479.94
591.06
257.26
210.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

29.84

Lower than Peers by 8.06

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
29.84
32.11
-504.23
24.21
-33.82
Peer Median
37.91
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

5.92

Lower than Peers by 1.78

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
5.92
3.93
2.45
1.80
1.89
Peer Median
7.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
--
--
--
--
Peer Median
0.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

19.79

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
19.79
19.27
43.73
10.89
12.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

5,694

Higher than Peers by 3,124

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
5,694
--
--
--
--
Peer Median
2,569
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...